Dr. Brandon Parrott

Licensure

State of Florida – Department of Health
Medical Doctor – Active
ME #102018 – Issued 2008

State of North Carolina – NC Medical Board
Medical Doctor – Active
Certificate #217718 – Issued 2016

State of Tennessee – Division of Health-Related Boards
Medical Doctor – Inactive
MD 45763 – Issued December 2009

American Board of Ophthalmology – Board Certified
United States Medical Licensing Examination (USMLE) – #5-025-890-4
Step I (Pass / 99 / 258)
Step II (Pass / 99 / 260)
Step III (Pass / 98 / 237)

Professional Affiliations 

Surgeon VitreoRetinal Associates
June 2017 – present
Gainesville, FL

Surgeon Center for Sight
May 2012 – May 2017
Sarasota, Florida

Surgeon Tennessee Retina, P.C.,
August 2010 – March 2012
Nashville, Tennessee

Instructor – Chief Resident
July 7th, 2009 – July 7th, 2010
Bascom Palmer Eye Institute (BPEI) / University of Miami
Miami, Florida

Fellowship Vitreoretinal Fellow
July 7th, 2008 – July 7th, 2009
Bascom Palmer Eye Institute (BPEI) / University of Miami
Miami, Florida

Residency Bascom Palmer Eye Institute / Jackson Memorial Health System,
July 1st, 2005 – June 30th, 2008
Miami, Florida
Ophthalmology Residency

Internship
Christus St. Joseph Hospital
June 18th, 2004 – June 20th, 2005
Houston, Texas
Transitional Year Internship

Honors and Awards

2016                Top Doctor – Castle Connolly
2011                 Top Ophthalmologist – International Association of Healthcare Professionals
2010-15           Compassionate Doctor Award – Patients’ Choice Organization
2005               In-service Exam Award – Christus St. Joseph Hospital
2004               Most Outstanding Performance in the Clinical Sciences – BCM MD/PhD program
2004               Alpha Omega Alpha Honor Society – BCM
2002               Best Oral Abstract Presentation – Center for Cell and Gene Therapy Symposium – BCM
2001                First Place Poster Presentation – Center for Cell and Gene Therapy Symposium – BCM
2001                First Place Outstanding Platform Presentation – Baylor College of Medicine MD/PhD Symposium – BCM
2001                First Place Speaker Award – Department of Immunology Student Symposium – BCM
1997                 Honors for Academic Performance in the Basic Sciences – BCM
1995-2004     Presidential Scholarship Award – BCM
1995-2004     NIH-Medical Scientist Training Program Fellowship – BCM
1995                Chancellor’s Citation for Extraordinary Academic Achievement – UTK
1995                L. Raymond Shobe Award for Leadership and Academic Excellence in Engineering – UTK
1996                Engineering Science and Mechanics Outstanding Student Scholarship – UTK
1994                Most active member award – Alpha Epsilon Delta (Pre-medical Honor Society) – UTK
1994                Inducted into Tau Beta Pi (Engineering Honor Society)
1990-95         Whittle Scholarship for Leadership and Academic Achievement – UTK
1990               Tennessee Academic Scholar
1990               National Merit Finalist
1990               First Place in the State of Tennessee in TMTA Advanced Calculus Competition

Publications

Kuriyan, AE, Albini TT, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB, Rosenfeld Pj, Flynn HW, Goldberg JL: Vision loss after intravitreal injection of autologous “stem cells” for AMD. New England Journal of Medicine 2017: 376:11:1047-1053.

Wykoff CC, Parrott MB, Flynn HW Jr, Shi W, Miller D, Alfonso EC: Nosocomial acute-onset
postoperative endophthalmitis at a university teaching hospital (2002-2009). American Journal of Ophthalmology 2010: Sep 150(3):392-398.

Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, Davis RP, Olmos LC, Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA: Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clinical Ophthalmology 2010: May 25(4):519-524.

Parrott MB: Evolution of the treatment of neovascular AMD in the age of anti-VEGF agents. The Ophthalmology Report 2010: 3(3):16-20.

Parrott, MB: The evolution of current and future treatments for neovascular AMD. The
Ophthalmology Report 2009: 2(2):16-20.

Campos SK, Parrott MB, Barry MA: Metabolically biotinylated pIX-modified adenovirus for single-step affinity purification of viral vectors. Molecular Therapy 2004: 9(6):942-54.

Blum JS, Parrott MB, Mikos AG and Barry MA: Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells. Journal of Orthopaedic Research 2003: 22(2):411-416.

Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, and Barry MA: Metabolically biotinylated adenovirus for cell-targeting, ligand screening, and vector purification. Molecular Therapy 2003: 8(4):688-700.

Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA: Selection of chronic lymphocytic leukemia targeting peptides. Cancer Research 2003: 63(17):5213-5217.

Barry MA, Campos SK, Ghosh D, Adams KE, Mok H, Mercier GT, and Parrott MB: Biotinylated gene therapy vectors. Expert Opinion in Biological Therapy 2003: 3(6):925-940.

Barry MA, Takahashi S, and Parrott MB: Selection of Peptides on Phage. In Vector Targeting for Therapeutic Gene Delivery. (DT Curiel and JT Douglas Eds.) John Wiley & Sons, Inc. New York, NY 2002.

Parrott MB and Barry MA: Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. BBRC 2001: 281:993-1000.

Parrott MB and Barry MA: Metabolic biotinylation of recombinant proteins in mammalian cells and in mice. Molecular Therapy 2000: 1(1):96-104.

Clinical Research Protocols

HAWK – NCT02307682 – Efficacy and Safety of RTH258 Versus Aflibercept – The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye. – Alcon.

PROXIMA A – NCT02479386 – Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration – This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. – Hoffmann-La Roche.

CEDAR – NCT02462928 – Safety and Efficacy Study of Abicipar Pegol in Patients With
Neovascular Age-related Macular Degeneration – This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration. – Allergan.

ORBIT – NCT02079883 – Ocriplasmin Research to Better Inform Treatment – Multicenter, prospective, observational, Phase 4 study assessing clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes. – Thrombogenics.

SHORE – NCT01277302 – A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion – This was a Phase IV multicenter, randomized, open-label study, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). – Genentech.

FOVEA (FOV2304) – NCT01319487 – Safety and Efficacy Study of Topical Administration
of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy – The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment. – Fovea Pharmaceuticals SA.

Novartis HMT – NCT01542866 – A 16-Week Evaluation of the Novartis Health Management Tool (HMT) in Age-Related Macular Degeneration – This is a prospective pilot study to evaluate the usability and applicability of a self-monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age-Related Macular Degeneration (AMD) to detect a potential change in disease status. – Novartis Pharmaceuticals.

DODO (FVF4155s) – NCT00533520 – Evaluation of Dosing Interval of Higher Doses of
Ranibizumab – Phase 4 study to test the safety, tolerability and effectiveness of a higher doses (1.0 mg and 2.0 mg) of ranibizumab versus the standard dose (0.5 mg), in adults with age-related macular degeneration who have never been treated with ranibizumab. – Genentech.

VISTA – NCT01363440 – Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema – The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection on the best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME) with central involvement.- Regeneron Pharmaceuticals.

Foresee Home Device Study (PT US 001) – NCT01334294 – Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age-Related Macular Degeneration. – The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT). – Notal Vision Ltd.

MAHALO – NCT01229215 – A Study of Safety, Tolerability, and Evidence of Activity of
FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy – Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy. – Genentech.

Research Experience

1998-2002 Baylor College of Medicine – Houston, TX
Department of Immunology and the Center for Cell and Gene Therapy
Advisor: Michael A. Barry, Ph.D.
M.D./Ph.D. Candidate – investigated the targeting of retroviral and adenoviral vectors to selected cell types by modifying the viral envelopes and capsid proteins of gene therapy viral vectors

1994-1995 University of Tennessee School of Veterinary Medicine – Knoxville, TN
Department of Orthopedic Surgery
Advisor: Jack Wasserman, Ph.D.
Biomedical Engineering Honors Thesis – tested structural integrity and compared biomechanical properties of a novel PMMA trans-hock external fixation device versus a traditional KE stainless-steel fixation device

1992-93 Oak Ridge National Laboratory – Oak Ridge, TN
Chemical Engineering Division Consultant – completed uranium contamination resorption project and trained post-doctoral engineer in newly established protocols

1992 Oak Ridge National Laboratory – Oak Ridge, TN
Chemical Engineering Division Research Intern – assisted in the design and testing of a biologically based uranium absorption system for the purification of uranium-contaminated water

1991 Oak Ridge National Laboratory – Oak Ridge, TN
Energy Sciences Division Research Intern – investigated enhancing the efficiency of heat pump technology through innovative design and use of computer models to test the efficiency of prototype heat pumps

Oral Presentations

Nov 2015 Oral Platform Presentation – Vision Loss Consequent to Intravitreal Stem Cell Injection
Albini TA, Kuriyan AE, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB, Rosenfeld PJ, Flynn HW
2015 Annual Meeting – American Academy of Ophthalmology – Las Vegas, NV

Nov 2008 Poster – Nosocomial Acute-onset postoperative endophthalmitis at a university teaching hospital Wykoff CC, Flynn HW, Miller D, Parrott MB, Murray TG, Smiddy WE, Davis JL
2008 Annual Meeting – American Academy of Ophthalmology

Nov 2007 Poster – Intravitreal bevacizumab use for progressive ROP and Best disease related choroidal neovascular membranes
Parrott MB, Murray, TG, and Berrocal AM
2007 Annual Meeting – American Academy of Ophthalmology

June 2007 Oral Platform Presentation – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes
Parrott MB, Wykoff CC, and Flynn HW
43rd Annual Bascom Palmer Eye Institute Resident’s Day – Miami, FL

May 2007 Poster – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes
Parrott MB, Wykoff CC, Miller D, Newton J, and Flynn HW
ARVO 2007 Annual Meeting – Fort Lauderdale, FL

June 2003 Oral Platform Presentation – Metabolically Biotinylated Viruses for Vector Targeting and Purification Campos SK, Parrott MB, Adams KE, and Barry MA
Sixth Annual Meeting of the American Society of Gene Therapy – Washington, DC

March 2003 Poster – Metabolically biotinylated gene therapy vectors for vector targeting and purification
Campos SK, Parrott MB, Adams KE, Blum JS, Mok H, Muzykantov V, and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

March 2003 Poster – Selection and application of CLL-targeting peptides using peptide-presenting phage libraries
Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

Jan. 2003 Poster – Apoptosis, mitotic rate, and age correlations in the regression of periorbital hemangiomas
Parrott MB, Font RL, and Chevez-Barrios P
Eighty-Second Annual Texas Society of Pathologists Meeting – Houston, TX

June 2002 Oral Platform Presentation – Metabolically biotinylated adenoviral vectors for targeted gene therapy
Parrott MB and Barry MA
Fifth Annual Meeting of the American Society of Gene Therapy – Boston, MA

May 2002 Oral Platform Presentation – Use of in vivo biotinylated adenoviral vectors for targeted gene therapy
Parrott MB and Barry MA
Forty-Third Annual National Student Research Forum – Galveston, TX

Dec. 2001 Poster – Selection of leukemia-targeting peptides using peptide presenting phage libraries
Takahashi S, Barry ME, Parrott MB, Brenner MK, and Barry MA
Forty-Third American Society of Hematology Annual Meeting – Orlando, FL

June 2001 Poster – Metabolically biotinylated gene therapy vectors
Parrott MB and Barry MA
Fourth Annual Meeting of the American Society of Gene Therapy – Seattle, WA

March 2001 Oral Platform Presentation – Metabolically biotinylated adenoviral and retroviral vectors
Parrott MB and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

June 2000 Poster – Metabolic biotinylation of recombinant proteins for viral gene therapy vector targeting
Parrott MB and Barry MA
Third Annual Meeting of the American Society of Gene Therapy – Denver, CO

March 1999 Poster – Selecting lung targeting peptides in vivo
Parrott MB and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

Teaching Experience

2009-2010 –   Chief Resident, BPEI
2006-2009 –  Teaching Assistant for Neuro-Ophthalmology Course, BPEI
1997-2004 –   Teaching Assistant and Graduate Lecturer, Department of Immunology, BCM
2003 –             Conference Leader, Department of Pathology, BCM
1996-1999 –   Conference Leader and Graduate Lecturer, Physiology, BCM
1996-2000-   Student Affairs Tutor, Biochemistry and Physiology, BCM
1995 –              Engineering Specialty Course – Tennessee Governor’s School for the Sciences, UTK

Grants and Fellowships

2003-2004 –  American Medical Association Foundation Research Seed Grant
1999-2002 –   National Research Service Award from National Institutes of Health
1995-2004 –   National Institutes of Health – Medical Scientist Training Program Grant

Professional Organizations

American Society of Retina Specialists
American Academy of Ophthalmology
Association for Research in Vision and Ophthalmology
Alpha Omega Alpha Honor Medical Society
American Society for Gene Therapy
Tau Beta Pi (Engineering)
American Medical Student Association
Texas Medical Student Association
Texas Society of Pathologists
Baylor Pediatrics Student Association – Research Coordinator